Case Type: Mergers & Acquisitions

Univar Solutions Inc. (NYSE: UNVR), relating to its sale to affiliates of Apollo Global Management, Inc. Under the terms of the agreement, UNVR shareholders will receive $36.15 in cash per share they own.

Cvent Holding Corp. (NASDAQ: CVT), relating to its sale to equity funds managed by Blackstone Inc.

Qualtrics International Inc. (NASDAQ: XM), relating to its proposed sale to Silver Lake. Under the terms of the agreement XM shareholders are expected to receive $18.15 in cash per share they own.

Seagen, Inc. (NASDAQ: SGEN), relating to its proposed sale to Pfizer Inc. Under the terms of the agreement SGEN shareholders are expected to receive $229.00 in cash per share they own.

Provention Bio, Inc. (NASDAQ: PRVB), relating to its proposed sale to Sanofi. Under the terms of the agreement PRVB shareholders are expected to receive $25.00 in cash per share they own.

Kimball International, Inc. (NASDAQ: KBAL), relating to its proposed sale to HNI Corp. Under the terms of the agreement KBAL shareholders are expected to receive $9.00 in cash per share they own.

Diversey Holdings, Ltd. (NASDAQ: DSEY), relating to its proposed sale to Solenis. Under the terms of the agreement DSEY shareholders are expected to receive $8.40 in cash per share they own.

Radius Global Infrastructure, Inc. (NASDAQ: RADI), relating to its proposed sale to EQT Active Core Infrastructure and Public Sector Pension Investment Board. Under the terms of the agreement, RADI shareholders are expected to receive $15.00 in cash per share they own.

TCR² Therapeutics Inc. (NASDAQ: TCRR), relating to its proposed sale to Adaptimmune Therapeutics plc. Under the terms of the agreement, TCRR shareholders are expected to receive 1.5117 shares of Adaptimmune per share they own.

Adaptimmune Therapeutics plc (NASDAQ: ADAP), relating to its proposed merger with TCR² Therapeutics Inc. Under the terms of the agreement, ADAP shareholders are expected to own approximately 75% of the combined company.